GEORGE KELLY SIBERRY, M.D.

Plain English
This study looked at how to better support key populations (like men who have sex with men, sex workers, and drug users) who are greatly affected by HIV and have trouble accessing healthcare. It found that three community-based programs in Vietnam, Nigeria, and Eswatini successfully combined HIV services (like testing and treatment) with general healthcare (like mental health support and disease screenings), making it easier for these individuals to get the help they need in safe environments. These integrated services can significantly improve health outcomes for these groups, especially in places where there is still a lot of stigma and legal barriers. Who this helps: This benefits people in key populations who face challenges accessing health care.

Plain English
This study looked at the safety of a medication called tenofovir disoproxil fumarate (TDF) in women living with HIV who were breastfeeding. Researchers found that women taking TDF experienced some decrease in kidney function during the postpartum period, with a decrease in creatinine clearance of about 11.4 mL/min at six weeks, but these changes were not clinically significant by the end of the study. The findings are important because they show that TDF is generally safe for breastfeeding mothers and does not pose a serious risk to their kidney health. Who this helps: This helps breastfeeding mothers living with HIV and their healthcare providers.

Plain English
This study looked at the effects of a medication called Tenofovir disoproxil fumarate (TDF) used by pregnant women with HIV on their newborns who were not infected with the virus. Researchers found that these babies had a faster decrease in phosphate reabsorption in their kidneys—0.58 units per day compared to 0.08 for babies not exposed to the drug—as well as lower levels of vitamin D in their blood, with exposed babies averaging 22 ng/mL versus 26 ng/mL for unexposed ones. This matters because it highlights potential kidney and bone issues in newborns from mothers who take TDF during late pregnancy. Who this helps: This information is beneficial for healthcare providers and mothers with HIV.

Plain English
This study focused on how to prevent babies from getting HIV from their mothers during breastfeeding. Researchers found that many current programs to provide postnatal prophylaxis (PNP) are not working effectively, especially in areas where fewer women attend antenatal care or get tested for HIV. For example, some programs give all infants exposed to HIV a stronger treatment plan, while better-performing programs use more tailored approaches based on risk levels. Who this helps: This research benefits infants exposed to HIV and their mothers by improving strategies to prevent HIV transmission.

Plain English
This study looked at the bone and kidney health of infants whose mothers received a specific HIV treatment (tenofovir) compared to those who received a different preventive medicine (nevirapine). Researchers found that at 26 weeks, infants in the tenofovir group had a lower bone mineral content, averaging 2.64 grams compared to 2.77 grams in the nevirapine group, which means the bone growth in the tenofovir group was less effective. However, both groups showed no significant kidney safety issues. Who this helps: This research helps healthcare providers and mothers making decisions about HIV treatment options during breastfeeding.

Plain English
This study looked at the differences between men and women in how well they control HIV viral load and their reported death rates in 21 African countries supported by a U.S. health program. It found that while 93% of women achieved good viral load suppression compared to 92% of men, men had a higher reported death rate of 2.37 per 1000 people, versus 1.51 for women. Understanding these differences is crucial for improving healthcare strategies and outcomes for people living with HIV. Who this helps: This research benefits patients and healthcare providers working in HIV treatment and prevention.

Plain English
This research study looked at the deaths of children under 5 years old who are living with HIV and receiving treatment called antiretroviral therapy (ART) across 28 countries supported by a global health initiative. Over two years, nearly 12,000 infants and about 105,000 children aged 1-4 were receiving ART, and it was found that 4.9% of infants and 2.5% of young children died annually, which is significantly higher than the death rates of older children and adults on the same treatment. This is important because it shows that very young children with HIV face higher risks and may not be getting the healthcare they need compared to older groups, highlighting the need for improved health services for these vulnerable children. Who this helps: This helps young children living with HIV and their families.

Plain English
This study looked at how the PEPFAR program, which supports HIV services in Africa, adjusted its strategies during the COVID-19 pandemic. Researchers found that to maintain HIV treatment during COVID-19, PEPFAR shifted from simply protecting existing services to restoring and enhancing them, focusing on personalized care. This is important because keeping HIV services running smoothly helps prevent setbacks in controlling the HIV epidemic in Africa, especially as new COVID-19 variants emerge. Who this helps: This helps patients living with HIV in Africa by ensuring they receive continuous care.

Plain English
This study looked at the benefits and costs of offering routine HIV testing and counseling to children aged 2-10 in South Africa, compared to not offering it at all. The results showed that testing helped increase the number of children diagnosed with HIV from 45.2% to 83.2% and those receiving treatment from 40.8% to 80.4%. It was found to be cost-effective, saving healthcare costs for every year of life gained in children, as long as the rate of undiagnosed HIV was higher than 0.2%. Who this helps: This helps children with undiagnosed HIV and their healthcare providers.

Plain English
This study focused on improving how new HIV drugs are tested for safety and effectiveness in pregnant women. Researchers found that existing drug approval timelines delay access to critical information, meaning pregnant women often don’t receive the best treatment options in a timely manner. They emphasized the need for faster studies and direct testing in pregnant women, which would help ensure that new antiretroviral drugs are marketed with important safety data from the start. Who this helps: This benefits pregnant women living with HIV and their healthcare providers.

Plain English
This study investigated the kidney health of pregnant women and their babies who were treated with an HIV medication called tenofovir disoproxil fumarate (TDF), compared to other standard treatments. In a group of over 3,500 pregnant women, those on TDF had slightly lower kidney function at delivery (with a measurement of about 147 mL/min) compared to other treatments, but this difference wasn't considered significant and there were no serious safety issues for mothers or infants. These findings are important because they indicate that TDF is safe for use during pregnancy, which can help prevent HIV transmission to babies. Who this helps: This helps pregnant women with HIV and their healthcare providers.

Plain English
This study looked at the effects of the medication alendronate on children and teens with HIV who also had low bone density. Over 48 weeks of treatment, bone density improved significantly, and this improvement continued for another 48 weeks. Even after stopping the medication, the gains in bone density mostly stayed the same for up to 48 weeks. Who this helps: This benefits children and adolescents living with perinatal HIV who are at risk of low bone density.

Plain English
This study looked at how antiretroviral drugs (ARVs) are tested for safety and effectiveness in pregnant women living with HIV. It found that most new ARVs are not studied in pregnant women until after they have been approved, potentially putting both mothers and their babies at risk. The researchers emphasized the need for quicker and safer ways to test these drugs in pregnancy so that women can access effective treatments sooner. Who this helps: This benefits pregnant women living with HIV and their infants by promoting safer medication options.

Plain English
This research examined how taking a specific HIV medication called tenofovir affects bone density in breastfeeding women. The study found that mothers who took tenofovir experienced a significant drop in bone density over 74 weeks—about 2.86% at the spine and 2.29% at the hip—compared to those whose infants received a different HIV prevention medication. This matters because lower bone density can increase the risk of fractures and other health issues for these mothers in the long run. Who this helps: This helps breastfeeding mothers living with HIV and their healthcare providers.

Plain English
This study looked at how breastfeeding from mothers on HIV treatment (mART) compares to giving infants a specific HIV preventer (iNVP) on the growth of babies who are not infected but were exposed to HIV at birth. Researchers followed 2,431 mothers and their 2,444 babies in several countries for up to 88 weeks. They found that, despite breastfeeding for a median of 70 weeks, both groups of infants had lower-than-normal height and weight at all check-in times, indicating ongoing growth issues; mothers on mART were more likely to have babies who were stunted (short for their age). Who this helps: This research benefits doctors and healthcare providers working with HIV-exposed infants.

Plain English
This study looked at how COVID-19 affected the way people with HIV receive their medication, specifically antiretroviral therapy (ART), through multi-month dispensing (MMD) policies in 21 countries supported by PEPFAR. Researchers found that MMD coverage increased significantly from 49% before COVID-19 to 72% during the pandemic, with pediatric clients seeing an increase from 27% to 51%. This is important because it shows that expanding the use of MMD helped ensure that people could continue their treatment without frequent trips to healthcare facilities, reducing their risk of COVID-19 exposure. Who this helps: This benefits patients living with HIV, particularly children and pregnant or breastfeeding women.

Plain English
This study looked at how well the drug alendronate helps improve bone health in children and teenagers infected with HIV from birth who have low bone mineral density (BMD). After 48 weeks, those taking alendronate experienced a significant increase in their lumbar spine BMD by 20%, compared to just a 7% increase for those not taking the drug. This is important because better bone health can help prevent osteoporosis and fractures later in life for these vulnerable patients. Who this helps: This benefits children and teenagers living with HIV.

Plain English
This study looked at the levels of two medications, tenofovir (TFV-DP) and emtricitabine (FTC-TP), in pregnant women who were part of a larger trial focused on preventing maternal and infant deaths. Researchers found that the average levels of TFV-DP were 706 and 806 fmol per punch at two different points during pregnancy, but higher levels weren't linked to more severe pregnancy issues like premature births or infant deaths. This matters because it suggests that taking these medications might not increase the risk of serious problems during pregnancy. Who this helps: This helps patients taking these medications during pregnancy and their healthcare providers.

Plain English
This study examined the use of two HIV treatments, dolutegravir and efavirenz, for new patients starting antiretroviral therapy in sub-Saharan Africa. The findings showed that using dolutegravir, even for women planning to become pregnant, could lead to nearly 11,000 years of healthy life gained each year and save about $2.9 million annually in healthcare costs for a country with 10 million adults. This is important because it means better health outcomes for patients and more effective use of healthcare resources. Who this helps: Patients starting HIV treatment, especially women planning to become pregnant.

Plain English
This study looked at two different HIV medications, raltegravir and efavirenz, in pregnant women who had never received HIV treatment before. Out of 408 women enrolled, 94% on raltegravir managed to lower their HIV levels to below 200 copies per mL, compared to 84% on efavirenz, showing that raltegravir is more effective (with a 10% difference). Both medications had similar safety profiles, with no treatment-related deaths reported. Who this helps: This benefits pregnant women living with HIV, ensuring better treatment options for them and their infants.

Plain English
This study looked at how PEPFAR, a major U.S. initiative for HIV care, adjusted its programs in sub-Saharan Africa during the COVID-19 pandemic to protect people living with HIV (PLHIV) while still providing necessary services. They found that implementing adaptive strategies helped maintain essential HIV services even as COVID-19 threatened the health systems in these areas. This is important because it ensures that the significant progress made in HIV prevention and treatment isn't lost during the pandemic. Who this helps: This helps patients living with HIV and healthcare providers in sub-Saharan Africa.

Plain English
This research focused on how the COVID-19 pandemic affected HIV services for pregnant and breastfeeding women, infants, children, and adolescents, especially in countries with limited resources. The study found that while adaptations were made to reduce COVID-19 risk, many didn't adequately address the specific needs of these groups. It highlights the importance of maintaining critical HIV services, like testing and treatment, while also ensuring safety, suggesting improvements like family-based care and using virtual tools to connect vulnerable individuals to necessary support. Who this helps: This benefits patients, particularly pregnant women and children living with or at risk for HIV.

Plain English
This study looked at whether a medication called tenofovir disoproxil fumarate (TDF), given to pregnant women to prevent the spread of hepatitis B to their babies, affected the bone health of both mothers and infants a year after birth. The findings showed that TDF did not significantly change the bone density of mothers or their infants one year after delivery. This is important because it confirms that using TDF during pregnancy and shortly after does not harm bone health, which reassures both patients and doctors about the safety of this treatment. Who this helps: This helps mothers with hepatitis B and their infants.

Plain English
This study looked at how well the drug lopinavir/ritonavir works and is tolerated in children with HIV when dosed according to World Health Organization guidelines based on weight. Out of 97 children involved in the study, 72% reached viral suppression after 24 weeks, and the drug was safe for most, with only 10% experiencing serious side effects. These findings show that dosing according to WHO guidelines is effective and safe, helping get more children living with HIV to a viral load that is undetectable. Who this helps: This helps children with HIV and their healthcare providers.

Plain English
This study looked at how well childhood vaccinations worked in children born with HIV (PHIV) compared to those who were HIV-exposed but not infected (HEU) in Latin America. They found that PHIV children were less likely to be fully vaccinated for diseases like measles and tetanus, with only 55.5% fully vaccinated for tetanus compared to 77.8% of HEU children. Even among those who were fully vaccinated, PHIV children had a lower immune response; for example, only 20.9% had immunity to hepatitis B compared to 37.8% of HEU children. This matters because it shows that PHIV children are at greater risk for diseases that vaccines can prevent, highlighting the need for better vaccination strategies for them. Who this helps: This helps children with HIV and healthcare providers working to improve vaccination coverage and outcomes.

Plain English
This study looked at preschool-aged children in the United States who were exposed to HIV in the womb but did not get the virus themselves. Researchers found that these children have a higher risk of language impairments by age 5 compared to normal population levels, particularly influenced by factors like being male or black and certain socioeconomic conditions, although their speech impairments were similar to those of the general population. Importantly, exposure to the medication Tenofovir was linked to a higher risk of speech impairments at age 3 but a lower risk of language impairments by age 5. Who this helps: This information is valuable for doctors and parents of HIV-exposed children, as it highlights the need for monitoring language development in this group.

Plain English
This study examines the delay between the development of drug formulations for adults and those for children, particularly in the context of HIV treatment, which currently takes 8 to 10 years longer for children. It introduces the Global Accelerator for Paediatric Formulations (GAP-f), a collaboration aimed at speeding up the development and availability of pediatric medications for HIV and other serious diseases in low- and middle-income countries. By enhancing cooperation among different stakeholders, this initiative aims to improve access to critical treatments for children, ultimately reducing infant mortality rates and combating infectious diseases. Who this helps: This helps children in low- and middle-income countries who need effective treatments for serious health issues.

Plain English
This study tested a new candidate vaccine for respiratory syncytial virus (RSV) in children aged 6 to 24 months. The vaccine was given as a single nasal dose and was found to be effective, with 90% of vaccinated children developing a strong immune response and 95% shedding the vaccine virus without serious illness. This is important because it shows that the vaccine can trigger a protective immune response against RSV, which can cause severe respiratory infections in young children. Who this helps: This helps infants and toddlers, particularly those at risk for severe RSV infections.

Plain English
Researchers studied a new RSV vaccine called RSVcps2 in children aged 6 to 24 months who had never been exposed to RSV before. They found that 85% of the vaccinated children got infected with the vaccine version of the virus, with 59% showing a strong immune response afterward. The vaccine was well tolerated, and importantly, it did not revert to a stronger form that could cause illness. Who this helps: This benefits young children at risk for severe RSV illness, as well as their parents and pediatric healthcare providers.

Plain English
This study examined whether a medication called tenofovir could help prevent pregnant women with hepatitis B from passing the virus to their babies at birth. Out of 147 infants born to mothers taking tenofovir, none were infected with hepatitis B, while 2% of infants born to mothers taking a placebo were infected. This is important because it shows that in places where infants already receive hepatitis B immune globulin and vaccines, adding tenofovir does not significantly reduce the risk of transmission. Who this helps: This benefits pregnant women with hepatitis B and their infants.

Plain English
This study looked at how to effectively monitor the delivery of differentiated antiretroviral therapy (ART) for HIV treatment, which aims to help more people access care without overusing resources. Researchers found that adding measures of how often patients receive their medication and attend clinic visits can improve the assessment of the program's effectiveness and efficiency. This matters because tracking these details helps ensure quality care while maintaining support for HIV treatment programs. Who this helps: This helps patients receiving HIV treatment and healthcare providers managing ART programs.

Plain English
This study focused on improving the availability of specialized medications for children with HIV in low- and middle-income countries. Currently, only 43% of children living with HIV are receiving proper treatment, just as global health goals aim to have 1.6 million children on these life-saving therapies by the end of 2018. The Global Accelerator for Paediatric Formulations (GAP-f) was established to speed up the creation and distribution of safer, more effective drug formulations for children, ensuring that they receive the care they need. Who this helps: This benefits children living with HIV, their families, and healthcare providers.

Plain English
This study looked at how to better identify and connect children and teens living with HIV to treatment in places where resources are limited. Researchers found five effective strategies, such as testing children in health facilities and supporting the needs of adolescents. These methods aim to reduce deaths related to HIV in young people, which is crucial for improving health outcomes. Who this helps: This helps children, adolescents, and their healthcare providers.

Plain English
This study focused on improving prevention for HIV in at-risk adolescents by testing a method that allows them to consent to participate in research about HIV prevention treatments. Researchers found that using this mature minor consent approach was safe and effective, leading to new guidelines for prescribing HIV prevention drugs (PrEP) to teenagers. This matters because it helps reduce new HIV infections in vulnerable youth, especially since infection rates are rising in this age group. Who this helps: At-risk adolescents and their healthcare providers.

Plain English
This study looked at how the drug tenofovir behaves in the bodies of women who are infected with hepatitis B but not HIV, during and after pregnancy. Researchers found that the amount of tenofovir in the women’s blood was about 20% lower while they were pregnant compared to after they gave birth, but this decrease did not lead to any cases of the virus being passed to the baby. This is important because it means that the current dosage of tenofovir does not need to change for pregnant women to effectively prevent the spread of hepatitis B to their children. Who this helps: This benefits women with hepatitis B who are pregnant and their newborns.

Plain English
This study examined how drug resistance affects the treatment of HIV in children living in low- and middle-income countries. It found that children are more likely to experience treatment failure due to drug resistance, which is worsened by issues like less effective medications and difficulties in sticking to treatment. Improving available medications and support for taking them is crucial to help these children achieve better health outcomes. Who this helps: This helps children living with HIV and the healthcare providers treating them.